Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment

Clinical trial NCT07199296 · RECRUITING

Trial details

NCT number: NCT07199296
Sponsor: Ruijin Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Mantle Cell Lymphoma (MCL)

Start date: 2025-07-01
Primary completion: 2028-07-01
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.